Roche wins FDA approval for first PTEN-loss companion diagnostic in prostate cancer
The FDA nod marks a step forward in precision oncology, linking molecular diagnostics more tightly to therapy selection for advanced prostate cancer
The FDA nod marks a step forward in precision oncology, linking molecular diagnostics more tightly to therapy selection for advanced prostate cancer
Subscribe To Our Newsletter & Stay Updated